Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators

Race Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead.

At the conference, Race presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room.

Watch the interview with Dr Peter Smith, Race’s Executive Chair below. Full article on the conference can be accessed here.